Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).

PHASE3TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 2, 2022

Primary Completion Date

July 25, 2022

Study Completion Date

November 30, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

Tozinameran - Standard dose

Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS\_CoV-2). A standard dose will be administered on day 0 of the study.

BIOLOGICAL

Tozinameran - fractional dose

Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS\_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.

BIOLOGICAL

Elasomeran - standard dose

"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study."

BIOLOGICAL

Elasomeran - fractional dose

"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study."

Trial Locations (1)

3010

Royal Children's Hospital, Melbourne

All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

collaborator

The Peter Doherty Institute for Infection and Immunity

OTHER

lead

Murdoch Childrens Research Institute

OTHER

NCT05228730 - Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV). | Biotech Hunter | Biotech Hunter